Aenova goes global

As the world depends on medicines and supplements for its health needs, top pharmaceutical companies rely on Aenova Group to supply the industry with high-quality capsules, tablets and other products.

Supporting clients across the whole value chain, Aenova develops, manufactures and packages a complete range of high-end solid, semi-solid and liquid dosage forms for pharmaceutical and health care products. With 2,500 people and 13 state-of-the-art manufacturing facilities, the company caters to more than 600 business-to-business clients worldwide.

"We've set up Aenova as a truly service-driven company," says CEO Heiner Hoppmann. "We've dominated all parts of the market with this mindset."

Aenova's research and development centre in Basel is behind many of the best-in-class technologies and formulations for softgel capsules and tablets. The company's offering also includes ointments, effervescent products, over-the-counter (OTC) items and generic formulations.

Aenova creates products based on client requirements or develops its own products for out-licensing. Shaped by evolving market trends, Aenova generates a new product range annually. This includes the sixth generation of its gelatin-free VegaGel capsules, which target health-conscious consumers and people whose ethical or religious beliefs disallow certain ingredients. Equipped with one of the world's best softgel technologies, Aenova can encapsulate any formulation without any leakages. The company continues to break ground into this field in co-operation with the University of Basel.

Looking to expand its Asian business to 10 per cent of net sales in the next five years, the company plans to establish a sales office in China next year. Following the acquisition of Temmler and Euro Vital Pharma, Aenova welcomes major customers that are dedicated to top quality and have a strong OTC presence on the mainland. The company is also moving into high-end cosmetics.